Cilo Cybin Holdings Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on Cilo Cybin Holdings's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | n/a |
| Return on equity | 0.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Cilo Cybin Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | 0 | 1 | 0 |
Quality Earnings: CCC has high quality earnings.
Growing Profit Margin: CCC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CCC's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CCC's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: CCC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: CCC's Return on Equity (0.9%) is considered low.